Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy.


Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 24 01 2019
revised: 03 04 2019
accepted: 22 04 2019
pubmed: 23 5 2019
medline: 19 12 2019
entrez: 23 5 2019
Statut: ppublish

Résumé

To develop an Eclipse plug-in (MLC_MODIFIER) that automatically modifies control points to expose fiducials obscured by MLC during VMAT, thereby facilitating tracking using periodic MV/kV imaging. Three-dimensional fiducial tracking was performed during VMAT by pairing short-arc (3°) MV digital tomosynthesis (DTS) images to triggered kV images. To evaluate MLC_MODIFIER efficacy, two cohorts of patients were considered. For first 12 patients, plans were manually edited to expose one fiducial marker. Next for 15 patients, plans were modified using MLC_MODIFIER script. MLC_MODIFIER evaluated MLC apertures at appropriate angles for marker visibility. Angles subtended by control points were compressed and low-dose "imaging" control points were inserted and exposed one marker with 1 cm margin. Patient's images were retrospectively reviewed to determine rate of MV registration failures. Failure categories were poor DTS image quality, MLC blockage of fiducials, or unknown reasons. Dosimetric differences in rectum, bladder, and urethra D1 cc, PTV maximum dose, and PTV dose homogeneity (PTV HI) were evaluated. Statistical significance was evaluated using Fisher's exact and Student's t test. Overall MV registration failures, failures due to poor image quality, MLC blockage, and unknown reasons were 33% versus 8.9% (P < 0.0001), 8% versus 6.4% (P < 0.05), 13.6% versus 0.1% (P < 0.0001), and 7.6% versus 2.4% (P < 0.0001) for manually edited and MLC_MODIFIER plans, respectively. PTV maximum and HI increased on average from unmodified plans by 2.1% and 0.3% (P < 0.004) and 22.0% and 3.3% (P < 0.004) for manually edited and MLC_MODIFIED plans, respectively. Changes in bladder, rectum, and urethra D1CC were similar for each method and less than 0.7%. Increasing fiducial visibility via an automated process comprised of angular compression of control points and insertion of additional "imaging" control points is feasible. Degradation of plan quality is minimal. Fiducial detection and registration success rates are significantly improved compared to manually edited apertures.

Identifiants

pubmed: 31116478
doi: 10.1002/acm2.12614
pmc: PMC6560246
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-124

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : MSK Cancer Center
ID : P30 CA008748

Informations de copyright

© 2019 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Références

Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1121-35
pubmed: 10863086
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9
pubmed: 22330997
Med Phys. 2014 Jul;41(7):071906
pubmed: 24989384
J Appl Clin Med Phys. 2016 Mar 08;17(2):473-486
pubmed: 27074467
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):922-931
pubmed: 29784460

Auteurs

Laura Happersett (L)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Ping Wang (P)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Pengpeng Zhang (P)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

James Mechalakos (J)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Guang Li (G)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Eleanor Eley (E)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Michael Zelefsky (M)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Gig Mageras (G)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Antonio L Damato (AL)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Margie Hunt (M)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH